public-benefit online pharmacy
Mark Cuban Cost Plus Drug Company
Industry Health
A public-benefit online pharmacy selling many generic medicines with published cost-plus pricing. Mark Cuban Cost Plus Drug Company scores well because the model leaves more value with stakeholders and the institution is less hostile to people with weak bargaining power, though person-dependent governance still limits the evaluation.
Why this matters: Cost Plus Drugs is not democratically owned, but its unusually transparent pricing and generic-drug focus make it one of the better consumer pharmacy options.
Letter grade C Performative Medium confidence (AI) Rubric gcd-rubric-v1
Final Score
41* C - Performative
C* Tentative scaffolding score. Not human-checked or final.
Represent this organization?
Request verification to have the evidence record checked against primary materials and organization-supplied documents. Verification does not buy a higher score; scores change only when review finds factual errors, omissions, or miscalibration.
Evaluation Overview
C - Performative
The score turns mainly on Extraction, with the largest penalty coming from Animal Testing.
Strengths
- Extraction7/10
- Solidarity with the Unemployed6/7
- Loss-Bearing Fidelity6/7
Penalties
- Animal Testing-6
- Reversibility-5
Evidence state
- ConfidenceMedium confidence (AI)
- ThoroughnessDeveloped (AI)
- Linked claims6
- Direct axis claims6
- Coverage6/13
Scoring Axes
| Axis | Score | Why this score |
|---|---|---|
Ownership
?
Control rights: shareholder-dominated at 0, worker cooperative control
at 10.
|
4 / 10 |
The linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Linked evidence
|
Governance
?
Binding decision authority: centralized control at 0, democratic
stakeholder control at 10.
|
5 / 10 |
The linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Linked evidence
|
Extraction
?
Surplus allocation, wage share, CEO pay ratio, margins, and structured
extraction judgment.
|
7 / 10 |
The linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Linked evidence
|
Labor Sovereignty
?
Worker power: coercive conditions at 0, co-determination or ownership at
7. Employee dissatisfaction matters only when source-backed evidence
shows concrete limits on worker agency, such as coercive scheduling,
retaliation, wage theft, harassment, unsafe conditions, suppression of
worker voice, or extreme turnover.
|
3 / 7 |
The linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Linked evidence
|
Solidarity with the
Unemployed
?
Treatment of exits and nonworkers, including severance, redeployment,
and non-competes.
|
6 / 7 |
Cost Plus Drugs is a privately controlled public-benefit online pharmacy, so it receives mission credit but not democratic ownership credit. Linked evidence
|
Loss-Bearing Fidelity
?
Willingness to absorb costs to preserve values, workers, users, and
public obligations.
|
6 / 7 |
Cost Plus Drugs is a privately controlled public-benefit online pharmacy, so it receives mission credit but not democratic ownership credit. Linked evidence
|
Market Conduct
?
Pricing fairness, switching costs, lock-in, and rent extraction.
|
5 / 5 |
Cost Plus Drugs is a privately controlled public-benefit online pharmacy, so it receives mission credit but not democratic ownership credit. Linked evidence
|
Product Integrity
?
Preservation of quality rather than degradation for monetization.
|
5 / 5 |
The company sells generic medicines through an online pharmacy model focused on access and price transparency, supporting Product Integrity for ordinary health needs. Linked evidence
|
Scale Integrity
?
Whether growth improves or degrades fairness and accountability.
|
5 / 5 |
Cost Plus Drugs is a privately controlled public-benefit online pharmacy, so it receives mission credit but not democratic ownership credit. Linked evidence
|
Penalties
| Penalty | Applied | Why this penalty |
|---|---|---|
Reversibility
?
Applied when positive conduct depends on current living leaders,
founders, family owners, or other person-contingent governance rather
than durable structure. Range: -5 to 0.
|
-5 |
Because Cost Plus Drugs is privately controlled and strongly identified with a living founder, its positive conduct is not locked by democratic ownership, describes conduct considered under Reversibility. Linked evidence
|
Animal Testing
?
Direct animal testing, contract animal testing, animal-testing-dependent
product development, or business lines where current safety/regulatory
approval normally relies on animal experiments. Stronger penalties apply
where animal testing is core, repeated, non-optional, or avoidable;
documented cruelty-free or non-animal methods reduce or eliminate the
penalty. Range: -8 to 0.
|
-6 |
Pharmaceutical, medical-product, or drug-development business models remain structurally tied to animal-testing systems in current regulated product development. Linked evidence
|
Bonus Credits
| Bonus | Credit | Why this credit |
|---|---|---|
Good Deal
?
Credit for unusually fair value: durable quality, fair pricing, low
lock-in, and clear customer surplus.
|
3 / 3 |
Cost Plus Drugs publishes a cost-plus pricing model that can create unusually clear customer surplus in generic medicines, supporting the Good Deal bonus. Linked evidence
|
Cost Transparency
?
Credit for clear posted prices, all-in fees, unit costs, public rate
cards, margin/cost visibility, or surplus-allocation transparency,
especially in markets where opaque quotes, hidden fees, or
individualized pricing are normal.
|
3 / 3 |
The company’s public model explains drug cost, markup, pharmacy labor, and shipping as explicit pricing components, supporting the Cost Transparency bonus. Linked evidence
|
Confidence Basis
Confidence Basis
Confidence is computed from the evidence trail and review state, not typed into the profile by hand.
Medium 71/100
6 verified linked claims 6 direct axis claims 0 disputed claims 6/13 components covered
This confidence label measures the source-backed evidence trail. AI-scaffolded scores remain tentative until human review.
Claim confidence 20/20
6 verified linked claims
Source quality 12/18
Best source per verified claim, weighted by institutional reliability
Direct axis-specific claims 6/18
6 direct claims across 13 active components
Dispute load 12/12
0 disputed claims on this entity
Recency 10/10
Newest accepted timestamp: May 13, 2026
Reviewer status 7/12
Human-reviewed components score higher than AI scaffolding
Component coverage 5/10
6/13 evidence-bearing components have direct support
Evidence State
Evidence State
Profile stateAI draft / human-pending
VerificationUnverified
ConfidenceMedium confidence (AI)
ThoroughnessDeveloped (AI)
Correction routeUse “Challenge this rating” for
factual errors, missing counterevidence, source problems, or calculation
mistakes.
Company responseCompany representatives can
submit source-backed corrections; payment never changes scores or
reviewer authority.
Claims and Sources
Claims are the evidence record. Each claim needs a source link, axis category, status, confidence level, and timestamp before it can support a score.
* Tentative scaffolding score. Not human-checked or final.1Cost Plus Drugs is a privately controlled public-benefit online pharmacy, so it receives mission credit but not democratic ownership credit.
- Cost Plus Drugs MissionGeneral web source · 58%
2The company sells generic medicines through an online pharmacy model focused on access and price transparency, supporting Product Integrity for ordinary health needs.
- Cost Plus DrugsGeneral web source · 58%
3Cost Plus Drugs publishes a cost-plus pricing model that can create unusually clear customer surplus in generic medicines, supporting the Good Deal bonus.
- Cost Plus Drugs MissionGeneral web source · 58%
4The company’s public model explains drug cost, markup, pharmacy labor, and shipping as explicit pricing components, supporting the Cost Transparency bonus.
- Cost Plus Drugs MissionGeneral web source · 58%
5Because Cost Plus Drugs is privately controlled and strongly identified with a living founder, its positive conduct is not locked by democratic ownership, describes conduct considered under Reversibility.
- Cost Plus Drugs MissionGeneral web source · 58%
6Mark Cuban Cost Plus Drug Company has drug/medical product development animal-testing exposure based on its listed business model and current profile description: A public-benefit online pharmacy selling many generic medicines with published cost-plus pricing. Mark Cuban Cost Plus Drug Company scores well because the model leaves more value with stakeholders and the institution i…
- Mark Cuban Cost Plus Drug Company public siteGeneral web source · 58%
- FDA: Animal Welfare, Testing and Research of FDA-Regulated ProductsPrimary public record · 100%
Help Improve This Profile
Submit source-backed evidence or challenge a specific claim, source, axis value, or calculation below.
How This Page Is Maintained
Evidence comes in through contributors, is checked by verifiers, and is synthesized by reviewers. Founder authority remains narrow and visible; scores recalculate when verified claims or the rubric change.
Civic Note
Incorporation, limited liability, market access, and other institutional privileges are public grants. Good Companies Directory treats those privileges as conditional on accountability to workers, users, communities, and the public.
Submit evidence for Mark Cuban Cost Plus Drug Company Add one source-backed fact for review.
Challenge this rating Point to a specific score, claim, source, or calculation problem.
Audit Log
Recent public changes for this company or group. The full audit log is part of the Transparency record.
No company-specific audit entries have been published yet.
View Full Audit Log